Brought to you by 
Warner-Lambert and Sankyo form 50/50 US joint venture
16 Oct 2000
Executive Summary
Warner-Lambert and Sankyo formed a 50/50 US joint venture Sankyo/Parke-Davis to co-promote two products: Sankyo's troglitazone (diabetes) and WL's Accupril (ACE inhibitor quinapril), replacing their 1991 deal for troglitazone.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Warner-Lambert and Sankyo form 50/50 US joint venture
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice